Cleared Traditional

K934178 - ACCUSCREEN 17-HYDROXYPROGESTERONE

K934178 is an FDA 510(k) clearance for ACCUSCREEN 17-HYDROXYPROGESTERONE, manufactured by Neometrics, Inc.. The device is a Class 1 Chemistry device with product code JLX cleared through the Traditional 510(k) pathway after a 580-day FDA review.

K934178 · Neometrics, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1995
Decision
580d
Days
Class 1
Risk

K934178 is an FDA 510(k) clearance for the ACCUSCREEN 17-HYDROXYPROGESTERONE. Classified as Radioimmunoassay, 17-hydroxyprogesterone (product code JLX), Class I - General Controls.

Submitted by Neometrics, Inc. (E. Northport, US). The FDA issued a Cleared decision on March 30, 1995 after a review of 580 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1395 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Neometrics, Inc. devices

FDA 510(k) Submission Details - K934178

510(k) Number K934178 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 27, 1993
Decision Date March 30, 1995
Days to Decision 580 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
492d slower than avg
Panel avg: 88d · This submission: 580d
Pathway characteristics
Predicate-based equivalence.

JLX Device Classification - Class 1, General Controls

Product Code JLX Radioimmunoassay, 17-hydroxyprogesterone
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1395
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Peers - JLX Radioimmunoassay, 17-hydroxyprogesterone

All 10
Devices cleared under the same product code (JLX) and FDA review panel - the closest regulatory comparables to K934178.
DELFIA NEONATAL 17A-OH-PROGESTERONE KIT
K042424 · Wallac OY · Sep 2004
AUTODELFIA NEONATAL 17A-OH-PROGESTERONE KIT
K042425 · Wallac OY · Sep 2004
BIO-RAD MICROPLATE 17-HYDROXYPROGESTERONE TEST
K973350 · Bio-Rad · Feb 1998
DSL ACTIVE 17A-OH PROGESTERONE RIA (DSL 5000)
K943148 · Diagnostic Systems Laboratories, Inc. · Nov 1994
DSL 17A-OH PROGERSTERONE (DSL #6800)
K894265 · Diagnostic Systems Laboratories, Inc. · Sep 1989
COAT-A-COUNT NEONATAL 17-ALPHA HYDROXPROG RIA KIT
K874782 · Diagnostic Products Corp. · Feb 1988